10.1007/s11011-020-00573-8 36
Comparing thyroid risk across GLP-1 receptor agonists Tirzepatide is not the only medication carrying a thyroid C-cell tumor boxed warning
Pain that comes after eating, when lying down, or when taking semaglutide is more likely to be from the stomach or esophagus
#Pfizer #NovoNordisk #Metsera #EliLilly #BiotechNews #PharmaDeals #HealthcareInnovation #PharmaNews #ObesityDrugs #GLP1 #Amylin #WeightLossMarket #LifeSciences #PharmaceuticalIndustry #DrugDevelopment #HealthcareTrends #BusinessStrategy #MergersAndAcquisitions #MetabolicHealth #ClinicalResearch #Biopharma #InvestmentNews #RAndD #MedicalInnovation #DrugDiscovery #BiotechInvesting #GlobalPharma #HealthcareBusiness #MarketWatch #InnovationInHealth To view or add a comment, sign in Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk
Fad diets often fail because they are difficult to maintain and dont address underlying factors like appetite regulation, energy balance, or lifestyle demands
HIGHLIGHTS: Stable BPC-157, a novel anti-ulcer peptide (1) BPC-157: Healing in different tissues Tendon Healing (4) Bone healing BPC-157 & Neuroprotective effect Effect on Spinal Cord Injury Blood Pressure Tendon Healing (4) Bone healing Stable BPC-157 as anti-ulcer agent (1) Stable gastric pentadecapeptide BPC 157 is a novel anti-ulcer peptide, used in trials for the treatment of ulcerative colitis and now multiple sclerosis, lethal dose (dosage required to kill 1% of the test population, LD1) not reported
